A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  • STATUS
    Recruiting
  • End date
    Oct 7, 2021
  • participants needed
    625
  • sponsor
    AbbVie
Updated on 30 May 2021
Investigator
AbbVie_Call Center
Primary Contact
Universitaetsklinikum Erlangen /ID# 203551 (8.7 mi away) Contact
+714 other location
endoscopy
adalimumab
ustekinumab
infliximab
abdominal pain
vedolizumab
crohn's disease
certolizumab pegol
mucosal inflammation

Summary

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Details
Condition Inflammatory bowel disease, Crohn's Disease, Crohn's Disease (Pediatric), crohns disease
Treatment Upadacitinib, Matching placebo for upadacitinib
Clinical Study IdentifierNCT03345836
SponsorAbbVie
Last Modified on30 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note